The trial, taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, enrolls a total of 45 healthy adults over a six-week time frame, aiming to establish that the vaccine is safe and induces a desired response from participants' immune systems, setting the stage for larger trials this year that will assess its efficacy.